{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:40:50Z","timestamp":1781764850356,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for treatment of anemia in dialysis-dependent chronic kidney disease (CKD) with a starting dose of 300\u00a0mg once daily (dose adjustments up to 600\u00a0mg). A recent phase 1b study evaluated the pharmacokinetics, pharmacodynamics, and safety of higher vadadustat doses (500\u2013900\u00a0mg) in healthy volunteers. Here we report the pharmacokinetic (PK), pharmacodynamic (PD), and safety characterization of higher doses of vadadustat in patients with CKD receiving dialysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This phase 1b, randomized, open-label study evaluated the pharmacokinetics and pharmacodynamics of vadadustat (600, 750, or 900\u00a0mg) in patients with CKD-related anemia receiving hemodialysis over a 10-day treatment period. Forty-six eligible patients were randomized to vadadustat 600, 750, or 900\u00a0mg daily or an intravenous erythropoiesis-stimulating agent. For vadadustat groups, blood samples for PK and PD analyses were collected on Day 1 and Day 8. PK analyses included area under the plasma concentration time curve (AUC) from dosing to last quantifiable concentration and to infinity, and to maximum plasma concentration (C\n                      <jats:sub>max<\/jats:sub>\n                      ). PD analyses measured serum erythropoietin (EPO), hemoglobin, and red blood cells (RBCs). Safety assessments included adverse events in the safety population (patients who received \u2265\u20091 dose of study drug). Patients underwent a 30-day safety follow-up period after the last dose of study drug.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the vadadustat groups, a dose-dependent increase in plasma exposure of vadadustat (C\n                      <jats:sub>max<\/jats:sub>\n                      and AUC) with modest accumulation was observed on Day 1 and Day 8. Vadadustat increased plasma EPO concentrations, with a variable EPO response observed in each group. Relative to baseline, mean hemoglobin and RBC levels remained unchanged, with no significant changes observed in any treatment group. Vadadustat was welltolerated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The current study characterized the PK and PD response (EPO and reticulocytes) and safety profile of vadadustat at doses of 600, 750, and 900\u00a0mg in patients with CKD receiving dialysis. Overall, vadadustat was well tolerated. These findings will contribute to the development of higher-dose regimens for further investigation in phase 3 studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov ID NCT03992066;\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03992066\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT03992066<\/jats:ext-link>\n                      ; Retrospectively registered on June 18, 2019. Accessed January 13, 2025.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-025-04367-x","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T17:24:01Z","timestamp":1754933041000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A randomized trial to evaluate the pharmacokinetics, pharmacodynamics, and safety of vadadustat in patients with anemia associated with chronic kidney disease receiving hemodialysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Pamela","family":"Navarro-Gonzales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit","family":"Chavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven K.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Dykstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"issue":"1","key":"4367_CR1","doi-asserted-by":"publisher","first-page":"e84943","DOI":"10.1371\/journal.pone.0084943","volume":"9","author":"ME Stauffer","year":"2014","unstructured":"Stauffer ME, Fan T.Prevalence of anemia in chronic kidney disease in the United States. PLoS One. 2014;9(1):e84943.","journal-title":"PLoS One"},{"issue":"5","key":"4367_CR2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nrneph.2013.21","volume":"9","author":"WH H\u00f6rl","year":"2013","unstructured":"H\u00f6rl WH. Anaemia management and mortality risk in chronic kidney disease. Nat Rev Nephrol. 2013;9(5):291.","journal-title":"Nat Rev Nephrol"},{"key":"4367_CR3","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2011111078","volume":"23","author":"JL Babitt","year":"2012","unstructured":"Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23:1631\u201334. https:\/\/doi.org\/10.1681\/ASN.2011111078.","journal-title":"J Am Soc Nephrol"},{"key":"4367_CR4","unstructured":"KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl. 2012;2(4)."},{"key":"4367_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1159\/000351175","volume":"37","author":"PA McCullough","year":"2013","unstructured":"McCullough PA, Barnhart HX, Inrig JK, et al. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol. 2013;37:549\u201358.","journal-title":"Am J Nephrol"},{"issue":"6","key":"4367_CR6","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.2215\/CJN.02380607","volume":"2","author":"S Fishbane","year":"2007","unstructured":"Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol. 2007;2(6):1274\u201382.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"4367_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1053\/j.ajkd.2015.06.030","volume":"67","author":"M Bonomini","year":"2016","unstructured":"Bonomini M, Del Vecchio L, Sirolli V, Locatelli F. New treatment approaches for the anemia of CKD. Am J Kidney Dis. 2016;67(1):133\u201342.","journal-title":"Am J Kidney Dis"},{"key":"4367_CR8","unstructured":"Nova Scotia Health Authority. Patient and Family Guide 2020. Erythropoiesis-Stimulating Agent (ESA) Therapy and Chronic Kidney Disease (CKD). https:\/\/www.nshealth.ca\/sites\/default\/files\/documents\/pamphlets\/1493.pdf. Accessed 22 Aug 2024."},{"key":"4367_CR9","first-page":"1703","volume":"27","author":"M Gauthier-Loiselle","year":"2021","unstructured":"Gauthier-Loiselle M, Michalopoulos SN, Cloutier M, Serra E, Bungay R, Szabo E, et al. Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective. J Manag Care Spec Pharm. 2021;27:1703\u201313.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"4367_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nrneph.2015.193","volume":"12","author":"PH Maxwell","year":"2016","unstructured":"Maxwell PH, Eckardt K-U. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat Rev Nephrol. 2016;12(3):157.","journal-title":"Nat Rev Nephrol"},{"key":"4367_CR11","doi-asserted-by":"crossref","unstructured":"Chertow GM, Pergola PE, Farag YMK, Agarwal R, Arnold S, Bako G, et al, PRO2TECT Study Group. Vadadustat in patients with anemia and non-dialysis-dependent CKD. N Engl J Med. 2021;384(17):1589\u2013600.","DOI":"10.1056\/NEJMoa2035938"},{"key":"4367_CR12","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","volume":"384","author":"KU Eckardt","year":"2021","unstructured":"Eckardt KU, Agarwal R, Aswad A, Awad A, Block GA, Bacci MR, et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. N Engl J Med 2021;384:1601\u201312.","journal-title":"N Engl J Med"},{"key":"4367_CR13","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s40265-020-01383-z","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A. Vadadustat: first approval. Drugs. 2020;80:1365\u201371.","journal-title":"Drugs"},{"key":"4367_CR14","unstructured":"Akebia Therapeutics, Inc. Akebia Therapeutics announces approval of vadadustat in Japan for the treatment of anemia due to chronic kidney disease in dialysis-dependent and non-dialysis dependent adult patients. Press release 29 June 2020; https:\/\/ir.akebia.com\/news-releases\/news-release-details\/akebia-therapeutics-announces-approval-vadadustat-japan (2020). Accessed 19 August 2024."},{"issue":"5","key":"4367_CR15","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.kint.2016.07.019","volume":"90","author":"PE Pergola","year":"2016","unstructured":"Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH.Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int. 2016;90(5):1115\u201322.","journal-title":"Kidney Int"},{"key":"4367_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/ndt\/gfy055","volume":"34","author":"VH Haase","year":"2019","unstructured":"Haase VH, Chertow GM, Block GA, et al. Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents. Nephrol Dial Transplant. 2019;34:90\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"4367_CR17","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/ajh.26644","volume":"97","author":"MJ Koury","year":"2022","unstructured":"Koury MJ, Agarwal R, Chertow GM, Eckardt KU, Fishbane S, Ganz T, et al. Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease. Am J Hematol. 2022;97:1178\u201388.","journal-title":"Am J Hematol"},{"key":"4367_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1124\/jpet.122.001126","volume":"383","author":"A Zuk","year":"2022","unstructured":"Zuk A, Si Z, Loi S, Bommegowda S, Hoivik D, Danthi S, et al. Preclinical characterization of vadadustat (AKB-6548), an oral small molecule hypoxia-inducible factor prolyl-4-hydroxylase inhibitor, for the potential treatment of renal anemia. J Pharmacol Exp Ther. 2022;383:11\u201324.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"4367_CR19","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/cpt.3342","volume":"116","author":"P Navarro-Gonzales","year":"2024","unstructured":"Navarro-Gonzales P, Ganz T, Pergola PE, Zuk A, Dykstra K. Pharmacokinetics, pharmacodynamics, and safety of vadadustat in healthy volunteers and patients with chronic kidney disease. Clin Pharmacol Ther. 2024;116(4):1052\u201361. https:\/\/doi.org\/10.1002\/cpt.3342.","journal-title":"Clin Pharmacol Ther"},{"key":"4367_CR20","unstructured":"Bio-Techne, R&D Systems. Human Erythropoietin Quantikine\u00ae IVD\u00ae ELISA Kit Package insert. Minneapolis, MN: Bio-Techne; 2024."},{"issue":"5","key":"4367_CR21","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000464476","volume":"45","author":"ER Martin","year":"2017","unstructured":"Martin ER, Smith MT, Maroni BJ, Zuraw QC, deGoma EM. Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease. Am J Nephrol. 2017;45(5):380\u201388.","journal-title":"Am J Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04367-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04367-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04367-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T10:34:10Z","timestamp":1757414050000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04367-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4367"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04367-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5396906\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the protocol, ethical principles of the Declaration of Helsinki, Good Clinical Practice, and International Conference on Harmonisation guidelines, as well as all other applicable regulations. Prior to study implementation, investigators obtained approval from a central institutional review board (IRB; Advarra IRB, Columbia, MD) except for one site that required a local IRB (Committee on the Protection of Human Subjects, Providence, RI). Reporting of data for this study adheres to CONSORT guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The purpose and nature of the study, as well as the possibility of adverse effects, were explained to study participants in understandable plain language terms, and written informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"P.N.G., D.W., S.K.B., and K.D. are employees of Akebia Therapeutics, Inc., and A.C. is a former employee of Akebia Therapeutics, Inc.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"453"}}